Classification
Compound class	Synthetic organic

IUPAC Name

3-methanesulfonamido-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide

Synonyms

AZD4901 | MLE4901

Comments

AZD2624 is an orally active antagonist of neurokinin receptor 3 (TACR3) developed initially by AstraZeneca as a potential therapeutic for schizophrenia. This compound was included in AstaZeneca's Open Innovation Pharmacology Toolbox (but has since been removed). Later renamed to AZD4901 it was acquired by Millendo Therapeutics who gave it a new research code of MLE4901 for their development programs for polycystic ovary syndrome and menopausal hot flushes. A successful Phase 2 study for the latter indication was reported in April 2017 [4]. A total of eight analogues are disclosed in the AstraZeneca composition of matter filing [5],

Database Links
CAS Registry No.	941690-55-7
GtoPdb PubChem SID	178102400
PubChem CID	23649245
Search Google for chemical match using the InChIKey	QYTBBBAHNIWFOD-NRFANRHFSA-N
Search Google for chemicals with the same backbone	QYTBBBAHNIWFOD
Search UniChem for chemical match using the InChIKey	QYTBBBAHNIWFOD-NRFANRHFSA-N
Search UniChem for chemicals with the same backbone	QYTBBBAHNIWFOD